Research Behind the Most Effective Treatment for Rosacea and Facial Redness

So-called “cosmeceutical” products sometimes base their claims of effectiveness on scientific results that are difficult to document. Consumers and medical professionals alike are better served by accessible, reliable scientific information when choosing a course of treatment.

In the case of PyratineXR®, the newest treatment choice for rosacea and facial redness, clear and supportive documentation is readily available. The clinical study, “Long-term efficacy and safety of topical PRK 124 (0.125%) Lotion (Pyratine XR®) in the treatment of mild to moderate rosacea“* set out to test the effectiveness and safety of treating rosacea with the new moisturizing lotion PyratineXR®, which contains the active ingredient PRK 124 (0.125% furfuryl tetrahydropyranyladenine). The study’s goals included evaluating the product’s long-term effectiveness for improving signs and symptoms of rosacea, and determining the potential for inflammation or other skin irritations.

Although the product falls into the category of a cosmeceutical (a combined pharmacological and cosmetic preparation that is not required to undergo testing by the United States Food and Drug Administration, or FDA), PyratineXR® was tested to standards usually applied when seeking rigorous FDA approval. The active ingredient, PRK 124, is developed from an advanced and revolutionary cytokinin (plant growth factor), shown to ensure skin vitality by improving production of collagen and elastin, increase production of cellular bioenergy, and remove harmful free radicals and cellular debris.

The study’s duration is especially significant to rosacea sufferers, who typically experience skin sensitivity. Rosacea is a chronic condition and therefore requires extended treatment periods, often resulting in irritation, and in turn, suspension of treatment. Conducted according to rigorous clinical practices, and in a university laboratory, the trial was designed to measure results when treating rosacea symptoms including papules, pustules, telangiectasias (spider veins) and erythema (facial redness).

Results were evaluated based on changes in signs and symptoms, as well as overall clinical improvement and skin tolerance, when checked at key milestones leading up to the complete 48 weeks. At 12 weeks, overall treatment was shown to be highly effective and well tolerated, with significant improvement in symptoms in 80 percent of participants. Subjects experienced a mean 44 percent reduction in erythema (facial redness) severity and a mean 89 percent reduction in inflammatory lesion count at week 48. Reductions were significant (P<0.05) in both erythema (redness) and lesions at weeks 24, 36, and 48.  Statistically significant (P<0.05) improvements in telangiectasia (spider veins), transepidermal water loss and dryness were noted. The clinical investigators and subjects found Pyratine®XR to be highly efficacious in reducing facial redness, inflammatory lesions and spider veins while improving skin texture. Throughout the course of the study, PyratineXR® was well tolerated, did not irritate skin and provided significant and essential moisturization.

*”Long-Term Efficacy and Safety of Topical PRK 124 (0.125%) Lotion (Pyratine-XR®) in the Treatment of Mild to Moderate Rosacea,” Anne Marie Tremaine MD, Arisa Ortiz MD, Laila Elkeeb MD, Minh Tran, Gerald Weinstein MD, Department of Dermatology, University of California, Irvine, Irvine, CA. Journal of Drugs in Dermatology, June 2010, Volume 9, Issue 6.


0 connections, 0 recommendations, 5 honor points.
Joined APSense since, October 25th, 2013, From Morro Bay, United States.

Created on Dec 31st 1969 19:00. Viewed 0 times.


No comment, be the first to comment.
Please sign in before you comment.